Genus plc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genus plc with three other
miscellaneous service companies in Europe:
sales of 1.82 billion Danish Kroner [US$271.84 million]
of which 100%
Clinigen Group PLC
(£339.90 million [US$429.17 million]
of which 41%
was Clinical Trial services), and
Bachem Holding AG
based in Switzerland
(236.48 million Swiss Francs [US$242.54 million]
of which 89%
was Active Pharmaceutical Ingredients).
During the year ended June of 2016, sales at
Genus plc were £388.30 million (US$490.28 million).
decrease of 2.6%
versus 2015, when the company's sales were £398.50 million.
Contributing to the drop in overall sales was the 42.0% decline
in Unallocated, from £13.80 million to £8.00 million.
There were also decreases in sales in
Operating Genus Abs (down 5.4% to £158.70 million)
However, these declines were partially offset by the increase in sales of
Operating Genus Pic (up 0.6% to £176.50 million)
Genus Asia (up 8.9% to £45.10 million)